Several types of endocrine drugs, including selective ER modulators (tamoxifen), aromatase inhibitors (AIs, such as letrozole and exemestane), and selective ER degraders (fulvestrant), are the most important therapies for ER+ breast cancer. Here, ESR1 is linked to breast carcinoma.